What sites for SBRT are thought to be more immunogenic for antigen presentation when combined with immunotherapy?

I am aware of only one prospective trial structured to approach this question to some extent. It was from Jim Welsh's team at MDAH and was presented at ASTRO this year.

http://www.redjournal.org/article/S0360-3016(17)33877-4/abstract

There was a hint that sequential ipilimumab followed by RT to lung lesions was a little bit better than sequential IPI followed by RT to liver lesions.

However, this area of study is evolving quickly, and IPI might be supplanted by other immunotherapy agents as the preferred ones to combine with RT, and the same effects might not be seen. By now everyone in the field will have heard of the PACIFIC trial results, for example.

The dozens of ongoing RT+immunotherapy trials will, we hope, eventually yield clinically us...